Cannabinoid Augmentation of Fear Response in Humans
Status: | Active, not recruiting |
---|---|
Healthy: | No |
Age Range: | 18 - 65 |
Updated: | 6/8/2018 |
Start Date: | May 2012 |
End Date: | May 2019 |
The purpose of this double blind, randomized, controlled, proof-of-concept study is to test
the effects of cannabinoid receptor augmentation on the facilitation of fear conditioning. On
three days over not more than two weeks, subjects will be trained to associate cues with two
different stimuli, then this association will be extinguished. Cannabinoid receptor
stimulation will be accomplished indirectly by harnessing the brain's capacity to
endocannabinoids through the administration of an enzyme (FAAH inhibitor) that prevents
degradation of anandamide. Subjects will receive placebo or the FAAH-inhibitor PF-04457845.
Some details of this study have not been disclosed to preserve the study design.
the effects of cannabinoid receptor augmentation on the facilitation of fear conditioning. On
three days over not more than two weeks, subjects will be trained to associate cues with two
different stimuli, then this association will be extinguished. Cannabinoid receptor
stimulation will be accomplished indirectly by harnessing the brain's capacity to
endocannabinoids through the administration of an enzyme (FAAH inhibitor) that prevents
degradation of anandamide. Subjects will receive placebo or the FAAH-inhibitor PF-04457845.
Some details of this study have not been disclosed to preserve the study design.
Inclusion Criteria:
- Between the ages of 18 and 65
- Male and female
- No major medical problems
Exclusion Criteria:
- Hearing problems
- Psychiatric or mental problems
We found this trial at
1
site
950 Campbell Ave
West Haven, Connecticut 06516
West Haven, Connecticut 06516
(203) 932-5711
Principal Investigator: Mohini Ranganathan, M.D.
Phone: 203-932-5711
VA Connecticut Healthcare System VA Connecticut encompasses an inpatient facility and Ambulatory Care Center in...
Click here to add this to my saved trials